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Armstrong et al 291Psoriasis is a chronic, inflammatory disease that
affects 3.2% of the adult US population or nearly 8
million Americans.1 Without appropriate treatment,
patients with psoriasis experience substantial
disease burden2,3 and profoundly decreased quality
of life.4,5 In addition to the cutaneous manifestations,Dr Gottlieb is currently affiliated with New York Medical College,
Valhalla, New York.
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have significantly reduced work productivity.4
Despite the availability of various treatment mo-CAPSULE SUMMARY
d Establishing treatment goals can help
improve patient outcomes.
d The US experts agreed that the target
response after initiating new psoriasis
treatments should be body surface area
1% or less. The target response at every
6 month maintenance evaluation should
be body surface area 1% or less.
d Treatment targets will establish
treatment expectations and encourage
providers to evaluate progress and
adjust treatments.dalities and continued intro-
duction of more efficacious
therapies for psoriasis,
nontreatment and under-
treatment of patients with
psoriasis remain a significant
problem in the United
States.3 Over 50% of patients
with psoriasis remain dissat-
isfied with their treatment.3
Efforts by various organiza-
tions to research and
advocate for improved
management have been
hampered by a lack of
defined treatment goals for
psoriasis in the United States.
As the international pso-
riasis community recognizes
the value of defining treatment goals for psoriasis,
several consensus efforts have emerged in other
parts of the world to define treatment goals.10,11
According to the European consensus of treatment
goals, treatment success is defined as a decrease in
Psoriasis Area and Severity Index (PASI) score of 75%
or greater that allows for treatment continuation;
treatment failure is defined as a decrease in PASI
score of less than 50% that necessitates a change in
treatment regimen. An intermediate response of
decrease in PASI score of 50% or greater but less
than 75% with Dermatology Life Quality Index
(DLQI) score 5 or less can lead to continuing current
regimen, whereas a decrease in PASI score of 50% or
greater but less than 75% with DLQI score greater
than 5 warrants modifying treatment regimen.10 In
Canada, a treat-to-target consensus defines Physician
Global Assessment (PGA) score of 0 (clear) as the
measurable target for patients and clinicians.11 To
date, there are no defined treatment targets for
psoriasis in the United States.
The rationale for defining treatment goals in the
United States is compelling and time-sensitive.
Without treatment goals, clinicians and patientshave no defined targets during the treatment course,
and substantial variability exists in treatment expec-
tation and quality of care. Therefore, determining
treatment targets is critical for defining treatment
expectations and optimizing psoriasis management
in the United States.
The overall purpose of establishing treatment
goals in the United States is to improve patient care
in psoriasis. Specifically, we aim to establish defined
treatment targets toward which both clinicians and
patients will strive in order to inform treatmentdecisions, reduce disease
burden, and improve pa-
tient outcomes in clinical
practice.
METHODS
Overall study design and
the Delphi process
To establish treatment
targets for psoriasis, we
conducted a consensus-
building study among
the current members of
the National Psoriasis
Foundation (NPF) Medical
Board and other providers
with significant clinical and
research expertise in psori-
atic diseases throughthe Delphi method. The Delphi had been informed
by structured input from patients and general der-
matologists. The overall process consisted of 3 steps:
(1) literature review; (2) pre-Delphi exercises con-
sisting of Delphi-question selection and discussion, a
survey of general dermatologists, and patient focus-
group discussions; and (3) the Delphi process
consisting of 4 Delphi rounds. This study was
approved by the University of Southern California
institutional review board (IIR00001886).
Literature review
The goal of the literature review was to examine
the existing treatment goals from outside the United
States to help guide the initial Delphi-item genera-
tion. Literature search was performed for articles
published before 2016 pertaining to treatment goals/
targets and treatment guidelines in psoriasis. The
reason for examining articles on both treatment
goals10-17 and treatment guidelines18-27 was to deter-
mine the range of published outcome measures and
cut-off values. The European consensus on defining
treatment goals for moderate to severe psoriasis,10
the Australian treatment goal consensus,15 and the
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ularly informative.
Pre-Delphi exercises
The pre-Delphi exercises consisted of: (1) Delphi
question selection and discussion; (2) survey of
general, practicing dermatologists; and (3) patient
focus-group discussions. First, based on the literature
review, we generated candidate-Delphi questions
and sought feedback from theDelphi participants via
electronic communications, 3 liveNPFMedical Board
meetings, and 1 additional teleconference.
Second, because the treatment targets are in-
tended to be used in clinical practice, we assessed
the current level of familiarity with and use of key
measurements (body surface area [BSA], PASI, PGA,
PGA3BSA, and DLQI) via a questionnaire distrib-
uted to general dermatologists.
Finally, we convened patients with psoriasis with
varying psoriasis severity and conducted an in-
depth, moderated, semistructured focus-group dis-
cussion to ascertain the patients’ perspective. Before
the focus-group discussion, the patients were
informed of its purpose and provided materials to
review. Patients expressed that, although BSA in
general captured psoriasis disease severity well,
factors such as location, symptoms, and quality of
life were also important. Patients also reported
excessive amount of time spent seeking adequate
psoriasis care because of their dissatisfaction with
prior treatments, providers, or both. Patients over-
whelmingly expressed the desire for complete clear-
ance so long as therapy had a favorable safety profile
and was convenient to administer. These findings
from the patient focus-group discussion were consis-
tent with clinical trial data.28
Delphi process
The Delphi process is a widely accepted form of
achieving consensus among a panel of experts.
Substantial heterogeneity exists in Delphi method-
ology in the literature.29 It is important to note that, in
the Delphi process, consensus rarely denotes 100%
agreement among the experts; rather, it is the result
of a process where the expert participants converge
in their opinions after multiple rounds of voting and
discussion. In this study, we adhered to the key
principles of the Delphi process: anonymity and
transparency. In this study, anonymity of individual
responses prevented authority, personality, or repu-
tation of some participants from dominating others
in the process; this also freed participants of their
own personal biases and thereby minimized ‘‘band-
wagon effect,’’ encouraged self-critique, and facili-
tated revision of earlier judgments.Four rounds of Delphi had been determined to be
the maximum number of rounds to achieve
consensus. These online-based Delphi rounds
occurred on November 19, 2015; February 3 and
24, 2016; andMarch 21, 2016. During each round, the
participants answered a structured questionnaire
and could provide written comments. After each
round, an anonymous summary of the group’s input
for each question was provided to all participants
along with anonymous, verbatim written comments.
For subsequent rounds, the participants were asked
to re-evaluate their responses in light of the re-
sponses of other members.
RESULTS
In all, 25 psoriasis experts consisting of current
members of NPF medical board and other psoriasis
experts participated in the Delphi process (Tables I
and II). Summary of treatment targets from the
Delphi consensus is shown in Table III.
Instrument for assessing treatment target
In the pre-Delphi exercise, general dermatologists
stated that BSA was the most familiar and used
measure in clinical practice (95% familiarity, 78%
utilization). DLQI and PGA3BSA were the least
familiar (26% and 11%, respectively) and least
frequently used (6% and 6%, respectively) measures
in clinical practice.
The Delphi participants were asked ‘‘In selecting
‘targets’ for the treat-to-target effort for patients with
psoriasis in the United States, which outcomes
instrument should be used to measure the target?’’
The most preferred measure was BSA from the
choices of PASI, PGA, BSA, PGA3BSA, and DLQI,
in all rounds of Delphi.
Timing for evaluation: Evaluation
posttreatment initiation and frequency of
evaluation during maintenance phase
When patients initiate a therapy, there is an initial
initiation phase, where the therapeutic effects of the
intervention begin to take place. This is followed by
amaintenance phase, where the therapeutic effect of
the intervention reaches a steady state (Fig 1).
Therapies have variable timing for onset of action,
and this may not necessarily correlate with a ther-
apy’s long-term steady-state effectiveness. We
sought to identify a single time point at which the
first evaluation after the start of treatment should take
place, regardless of therapy. Among the choices of
3 months, 4 months, and 6 months, the most
preferred time to perform this initial evaluation was
3 months through all Delphi rounds.
Table I. Instrument selection and treatment-target
Round 1 Round 2 Round 3
Choices Mean (SD) Median
(25th-75th
percentile)
Mean (SD) Median
(25th-75th
percentile)
Mean (SD) Median
(25th-75th
percentile)
Instrument selection for assessing treatment targets
PASI 2.5 (1.47) 2 (1-4) 2.11 (1.28) 2 (1-3) 2.53 (1.22) 2 (2-3)
PGA 3.5 (1.34) 3.5 (2.25-5) 3 (1.19) 3 (2-4) 3.26 (1.05) 3 (3-4)
BSA, most
preferred
4.06 (1.21) 4.5 (3.25-5) 4.22 (1.40) 5 (4-5) 4.53 (0.61) 5 (4-5)
PGA3BSA 3.22 (1.22) 4 (3-4) 3.56 (1.46) 4 (3-5) 3.47 (1.22) 4 (3-4)
DLQI 3.22 (1.17) 3 (3-4) 2.61 (1.20) 2.5 (2-4) 2.68 (1.00) 3 (2-3.5)
Treatment target scores during initial evaluation after starting a therapy
PASI 75 3.11 (1.60) 3.5 (2-4.75) 2.89 (1.57) 2.5 (2-4.75) 2.79 (1.36) 3 (1.5-4)
PASI 90 3.06 (1.47) 3.5 (2-4) 3.00 (1.46) 3 (2-4) 3.00 (1.37) 4 (1.5-4)
PASI 100 2.89 (1.45) 3 (2-4) 3.06 (1.59) 3 (2-5) 2.74 (1.41) 3 (1.5-4)
PASI = 0 2.88 (1.36) 3 (2-4) 2.44 (1.46) 2 (1-3) 2.63 (1.38) 2 (1.5-4)
PASI #1 2.61 (1.29) 2.5 (1.25-4) 2.39 (1.29) 2 (1.25-3.75) 2.37 (1.16) 2 (1-3)
PASI #3 2.50 (1.29) 2 (1.25-3.75) 2.06 (0.94) 2 (1.25-2) 2.26 (1.05) 2 (1-3)
PASI #5 2.22 (1.11) 2 (1-3) 1.89 (0.90) 2 (1-2) 2.00 (0.88) 2 (1-3)
PGA = 0, clear 3.39 (1.24) 3.5 (2.25-4) 2.83 (1.20) 3 (2-3.75) 2.89 (1.24) 3 (2-4)
PGA #1, clear or
almost clear
4.00 (1.19) 4 (3.25-5) 4.00 (1.08) 4 (4-5) 4.26 (0.87) 4 (4-5)
BSA = 0% 3.28 (1.07) 3 (3-4) 3.06 (1.35) 3 (2-4) 3.00 (1.37) 3 (2-4)
BSA #1%, most
preferred
3.35 (1.37) 4 (2-4) 3.94 (1.11) 4 (4-5) 4.42 (0.77) 5 (4-5)
BSA #3% 2.94 (1.11) 3 (2-4) 2.61 (1.14) 2.5 (2-3) 2.84 (1.26) 3 (2-3.5)
BSA #5% 2.56 (1.29) 2.5 (1.25-3.75) 1.94 (0.80) 2 (1-2.75) 2.16 (1.07) 2 (1-3)
PGA3BSA = 0 2.71 (1.36) 3 (2-4) 2.72 (1.53) 2.5 (1.25-3.75) 2.42 (1.26) 2 (1.5-3.5)
PGA3BSA #1 3.06 (1.39) 3 (2-4) 3.22 (1.26) 3.5 (3-4) 3.00 (1.20) 3 (2-4)
PGA3BSA #3 2.67 (1.33) 2.5 (2-3.75) 2.67 (1.28) 3 (1.25-3.75) 2.68 (1.20) 3 (2-3.5)
PGA3BSA #5 2.28 (1.32) 2 (1-3) 2.11 (1.18) 2 (1-3) 2.00 (0.88) 2 (1-2.5)
DLQI = 0 2.89 (1.32) 3 (2-4) 2.50 (1.29) 2.5 (1.25-3) 2.37 (1.34) 2 (1-3.5)
DLQI #1 3.17 (1.50) 3.5 (2-4) 3.61 (1.33) 4 (3-4.75) 2.74 (1.33) 3 (1.5-4)
DLQI #5 2.78 (1.35) 3 (2-4) 2.06 (1.00) 2 (1-3) 2.42 (1.26) 2 (1-3)
Treatment target scores during the maintenance phase
PASI = 0 2.89 (1.45) 3 (2-4) 2.89 (1.57) 2.5 (2-4.75) 2.68 (1.49) 2 (1.5-4)
PASI #1 2.83 (1.42) 3.5 (1.25-4) 2.83 (1.38) 3 (2-4) 2.47 (1.31) 2 (1-3.5)
PASI #3 2.67 (1.53) 2.5 (1-4) 2.22 (1.17) 2 (1-3) 2.21 (1.03) 2 (1-3)
PASI #5 2.22 (1.17) 2 (1-3) 1.72 (0.83) 2 (1-2) 1.84 (0.83) 2 (1-2.5)
PGA = 0 3.28 (1.36) 3.5 (2-4) 2.94 (1.51) 3 (2-4) 2.84 (1.34) 3 (2-4)
PGA #1 3.94 (1.35) 4 (4-5) 4.28 (0.96) 4 (4-5) 4.37 (0.96) 5 (4-5)
BSA 0% 3.17 (1.29) 3 (2-4) 2.94 (1.51) 3 (2-4) 2.95 (1.39) 3 (2-4)
BSA #1%, most
preferred
3.44 (1.34) 4 (2.25-4) 4.22 (1.00) 4 (4-5) 4.42 (0.84) 5 (4-5)
BSA #3% 2.83 (1.10) 3 (2-4) 2.50 (1.25) 2.5 (1.25-3) 2.74 (1.15) 3 (2-3.5)
BSA #5% 2.47 (1.18) 2 (2-3) 1.72 (0.89) 1.5 (1-2) 1.95 (0.91) 2 (1-2.5)
PGA3BSA = 0 2.83 (1.38) 3 (2-4) 2.50 (1.42) 2.5 (1-3) 2.47 (1.47) 2 (1-3.5)
PGA3BSA #1 3.06 (1.47) 3 (2-4) 3.00 (1.19) 3 (2.25-4) 2.95 (1.13) 3 (2-4)
PGA3BSA #3 2.72 (1.27) 3 (2-4) 2.67 (1.24) 3 (1.25-4) 2.58 (1.22) 2 (2-3.5)
PGA3BSA #5 2.33 (1.28) 2 (1-3) 2.00 (1.08) 2 (1-2.75) 1.89 (0.88) 2 (1-2)
DLQI = 0 3.00 (1.46) 3 (2-4) 2.78 (1.40) 3 (2-3.75) 2.32 (1.34) 2 (1-3)
DLQI #1 3.28 (1.45) 4 (2-4) 3.67 (1.41) 4 (2.5-5) 2.68 (1.45) 2 (1.5-4)
DLQI #5 2.67 (1.33) 3 (2-3) 2.06 (0.87) 2 (1.25-2.75) 2.26 (1.15) 2 (1-3)
Agreement scores 1-5, where 1 = strongly disagree and 5 = strongly agree, from Delphi rounds 1 through 3.
BSA, Body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment.
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Table II. Acceptable versus target body surface
area responses 3 months postinitiation
Instrument choices Mean (6SD)
Median
(25th-75th
percentile)
Acceptable BSA 3 mo after treatment initiation,
static measure
BSA #5% 3.28 (1.34) 4 (3.75-4.25)
BSA #3%,
most preferred
3.64 (1.22) 4 (4-5)
BSA #1% 3.20 (1.41) 3 (2.75-4.25)
Acceptable BSA improvement from baseline at 3 mo
posttreatment initiation, dynamic measure
$50% BSA improvement 3.12 (1.36) 3.5 (2-4)
$75% BSA improvement,
most preferred
3.84 (1.14) 4 (4-5)
$90% BSA improvement 3.60 (1.32) 4 (3-4.25)
Target BSA response 3 mo after treatment initiation, static
BSA #5% 2.80 (1.12) 3 (2-3.25)
BSA #3% 3.88 (1.01) 4 (4-5)
BSA #1%, most preferred 3.92 (1.26) 4 (3.75-5)
Agreement scores 1-5, where 1 = strongly disagree and
5 = strongly agree, from Delphi round 4.
BSA, Body surface area.
Table III. Summary of treatment targets from the
Delphi consensus
Preferred assessment
instrument in clinical
practice
BSA
Acceptable response after
treatment initiation
Either BSA #3% or BSA
improvement $75% from
baseline at 3 mo after
treatment initiation
Target response after
treatment initiation
BSA #1% at 3 mo after
treatment initiation
Target response during
maintenance therapy
BSA #1% at every 6 mo
assessment intervals
during maintenance
therapy
Treatment targets apply to plaque psoriasis, and they are to be
discussed in the context of individualized evaluation of benefit-
risk assessment and elicitation of patient preferences. They are not
to be used to deny access to therapies.
BSA, Body surface area.
Fig 1. Psoriasis. Therapeutic benefit during initiation and
maintenance phases.
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ments should be evaluated during the maintenance
phase, the participants were asked to choose among
frequencies of every 3 months, 6 months, and 1 year.
The participants preferred evaluation every 6months
during the maintenance phase in all Delphi rounds.
Acceptable versus target responses
posttreatment initiation
We asked the participants to indicate their
preferred level of acceptable versus target treatment
responses for each proposed instrument/measure at
3 months posttreatment initiation (Table II). An
acceptable response was what the participants
would consider as an adequate or sufficient level of
response to treatment. In comparison, a target
response was a goal toward which clinicians and
patients could strive.
By the final round of Delphi, for evaluation of
treatment response at 3 months posttreatment initi-
ation, the participants indicated either BSA 3% or less
or BSA improvement 75% or greater from baseline as
an acceptable response; they indicated BSA 1% or
less as the target response. For the every 6-month
evaluation during the maintenance therapy, BSA 1%
or less was again selected as the target response.
Fulfillment of a single criterion versus
multiple criteria
Treatment goals outside of the United States have
included the simultaneous fulfillment of multiplemeasures to determine treatment success or failure.
For example, European goals defined treatment
success as achieving both at least 75% improvement
in PASI score and a DLQI score of 5 or less.
For the US Delphi process, the participants were
asked if they preferred the use of a single criterion or
multiple criteria to determine treatment success. The
advantage of using a single criterion is ease of use in
clinical practice; the disadvantage is that the criterion
may not encompass other important aspects of the
disease burden. In comparison, the advantage of
using multiple criteria is the ability to capture mul-
tiple aspects of the disease burden; the disadvantage
relates to the increased administrative burden and
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Delphi rounds, the most preferred response was
the fulfillment of a single criterion to achieve
treatment goals.
Key summary of treatment targets
The Delphi consensus-building process gener-
ated the following findings (Table III). The most
preferred acceptable response to treatment at
3 months after treatment initiation is either BSA 3%
or less or BSA improvement 75% or greater from
baseline; the target response to treatment at 3months
after treatment initiation is BSA 1% or less; and the
target response during the every 6-month mainte-
nance evaluation is BSA 1% or less.
DISCUSSION
Establishing treatment goals and then treating-to-
target are evidence-based practices that have been
implemented with positive patient outcomes in
many disease areas such as diabetes, hypertension,
and rheumatoid arthritis.30-32 Although treat-to-
target efforts have been developed in other parts of
the world for psoriasis, to our knowledge, no such
organized, consensus-building effort has occurred in
the United States until now. From the perspective of
many stakeholders in psoriasis care including pa-
tients, clinicians, researchers, payers, and health
policy experts, an urgent need exists in the United
States to establish treatment expectations and
improve patient outcomes in clinical practice.
This consensus-seeking effort to establish treat-
ment targets in psoriasis has been a pivotal, iterative
endeavor organized by the NPF and conducted by a
panel of psoriasis experts. The expressed aim of this
treat-to-target effort was to establish treatment ex-
pectations and augment the overall quality of care for
patients with psoriasis in clinical settings. With the
defined treatment targets, both clinicians and pa-
tients can strive to adequately monitor disease pro-
gression and evaluate patient responses to
treatments in clinical practice.
Based on the discussion of the psoriasis experts,
below are ways in which the treatment targets can be
applied in clinical practice. The treatment targets are
goals toward which the clinicians and patients can
strive during the course of psoriasis management. At
this time, these targets provide guidance on what to
strive toward but not how to achieve these goals.
This is because the exact treatment decisions will
depend on a thorough benefit-risk assessment of the
patient by the clinician; this assessment needs to
account for the heterogeneity in patient demo-
graphics, clinical presentation, comorbidities, access
to medical care, and treatment preferences.Specifically, in clinical practice, the clinician and
the patient can use these treatment targets to monitor
disease progression and evaluate patient response to
treatment. If treatment goals are met at defined time
intervals, the patient’s disease state is thought to have
satisfied the current, established US treatment targets
for plaque psoriasis.
If the treatment goals are not met at defined time
intervals, this provides opportunities for the clinician
and patient to re-evaluate the disease state and the
existing treatment regimen. Not meeting the treat-
ment target should prompt discussions between the
provider and the patient about treatment options
based on benefit-risk assessment. These discussions
need to account for the multitude of clinical, socio-
economic, and behavioral factors that influence
treatment outcomes and may necessitate treatment
re-evaluations. The clinicians and patients should
discuss all relevant treatment options in order to
maximize the likelihood of meeting treatment tar-
gets; the management options may include but are
not limited to treatment escalation with the same
treatment, combination therapies with other agents,
or switching treatments. These discussions also need
to take into account a continual assessment of patient
satisfaction.
Importantly, we recognize that a real-world chal-
lenge to implementing these treatment goals is the
limited access to some therapies. Thus, we advocate
for increasing access to treatments such that pro-
viders and patients have the greatest number of
therapeutic options to achieve these goals.
Specifically, the payers should not apply these
established treatment targets to deny access to
existing therapies even if the patients have not met
the target; rather, payers should consider increasing
the accessibility of other therapeutic options,
including treatment escalation or combinations, to
help patients achieve treatment targets.
Over time, these targets will likely need to be
adjusted to account for improvements in instruments
to accurately capture psoriasis burden and to in-
crease feasibility in clinical practice. For now, BSA
was identified as the most practical instrument for
use by general dermatologists and the most appro-
priate instrument by experts. However, patients
communicated that BSA does not capture location,
symptoms, comorbidities, or life quality. Thus, we
encourage the development and validation of in-
struments, including patient-reported measures,
which are reliable, discriminating, and feasible to
administer in clinical settings.
In summary, the establishment of treatment tar-
gets is a critical, time-sensitive endeavor in the
United States that aims to establish expectations
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asis. Despite methodological heterogeneity across
various disciplines in the Delphi consensus-building
approach, the psoriasis experts in this Delphi pro-
cess converged in their assessment of treatment
targets. The treatment targets derived from this
endeavor are not only highly clinically relevant and
feasible to assess in practice but are also affirming to
patients’ expectations for disease clearance. These
treatment targets enable the providers and patients to
regularly reflect upon treatment progress and seek
ways to decrease disease burden. Efforts to create
valid, feasible, and clinically relevant measures in
psoriasis will positively impact future treat-to-target
endeavors. Finally, future research should focus on
how to make evidence-based therapeutic modifica-
tions to achieve these treatment targets, how to
increase patient access to therapies, and how imple-
mentation of treatment targets in the real world
impacts patient outcomes.
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